A purified preparation of type II porcine circovirus (PCV). Independent claims are also included for the following: (a) preparation of PCV (i) isolated from a physiological or tissue sample, particularly from a lesion, from a pig with symptoms of PMWS (porcine multisystemic wasting syndrome)； or (ii) produced by, and isolated from, in vitro cell cultures infected with the virus of (i)； (b) extract or culture supernatant, or antigen preparation, optionally purified, collected from in vitro cultures of cells infected with PCV； (c) vaccine containing the products of (b)； (d) DNA fragments (A) of 1767 bp (1), 1767 bp (2), 1767 bp (3), 1768 bp (4) or 1768 bp (6), or containing an open reading frame (ORF) of PCV； (e) polypeptides (I) encoded by (A) or these ORF； (f) in vitro expression vector containing (A), or these ORFs； (g) polypeptides (Ia), optionally purified, expressed from the vector of (f)； (h) subunit vaccine containing at least one (I) or (Ia), diluent or vehicle and optionally an adjuvant； (i) in vivo expression vector, integrated into a genome, containing (A) or the ORFs； (j) live or plasmid vaccine containing the vector of (j), and a diluent or vehicle； (k) probe or primer containing all or part of (A) or the ORFs； (l) mono- or poly-clonal antibodies raised against PCV, (I), (Ia) or their fragments； and (m) detection of PCV by identifying in a body fluid or tissue sample an antigen or antibody specific for the antigen. ACTIVITY : Antiviral. MECHANISM OF ACTION : Induction of an immune response against porcine circovirus； vaccine.
